A. Thomas McLellan

Last updated
A. Thomas McLellan
McLellan.jpg
Deputy Director of the Office of National Drug Control Policy
In office
2009–2010

A. Thomas McLellan (born May 29, 1949, in Staten Island, New York) [1] is the founder and chairman of the board of directors at the Treatment Research Institute, a not-for-profit research and development institute in Philadelphia. He served as deputy director of the Office of National Drug Control Policy from 2009 to 2012.

McLellan received his B.A. from Colgate University and his M.S. and Ph.D. from Bryn Mawr College. He received postgraduate training in psychology at Oxford University. He has since worked for the Veterans Administration Medical Center in Philadelphia and the University of Pennsylvania.

McLellan was the principal developer of the Addiction Severity Index (ASI) and the Treatment Services Review (TSR), widely used substance abuse instruments. He has served as an adviser to many government and nonprofit scientific organizations, including the Office of National Drug Control Policy, the National Practice Laboratory of the American Psychiatric Association, the Swiss National Science Foundation, the World Health Organization, the Greek government and Public Health England.

McLellan served as the deputy director of the Office of National Drug Control Policy under the Obama administration. [2]

Among McLellan's many honors and awards are the Life Achievement Award of the American Society of Addiction Medicine in 2003 and the 2002 award for Distinguished Contribution in Addiction Medicine from the Swedish Medical Association. He has served as editor-in-chief of the Journal of Substance Abuse Treatment. [3]

Related Research Articles

<span class="mw-page-title-main">Nils Bejerot</span> Swedish psychiatrist and criminologist (1921–1988)

Nils Johan Artur Bejerot was a Swedish psychiatrist and criminologist best known for his work on drug abuse and for coining the phrase Stockholm syndrome. Bejerot was one of the top drug abuse researchers in Sweden. His view that drug abuse was a criminal matter and that drug use should have severe penalties was highly influential in Sweden and in other countries. He believed that the cure for drug addiction was to make drugs unavailable and socially unacceptable. He also advocated the idea that drug abuse could transition from being a symptom to a disease in itself.

The Substance Abuse and Mental Health Services Administration is a branch of the U.S. Department of Health and Human Services. SAMHSA is charged with improving the quality and availability of treatment and rehabilitative services in order to reduce illness, death, disability, and the cost to society resulting from substance abuse and mental illnesses. The Administrator of SAMHSA reports directly to the Secretary of the U.S. Department of Health and Human Services. SAMHSA's headquarters building is located outside of Rockville, Maryland.

Andrea Grubb Barthwell worked in the White House under President of the United States George W. Bush as deputy director for Demand Reduction at the Office of National Drug Control Policy.

Substance dependence, also known as drug dependence, is a biopsychological situation whereby an individual's functionality is dependent on the necessitated re-consumption of a psychoactive substance because of an adaptive state that has developed within the individual from psychoactive substance consumption that results in the experience of withdrawal and that necessitates the re-consumption of the drug. A drug addiction, a distinct concept from substance dependence, is defined as compulsive, out-of-control drug use, despite negative consequences. An addictive drug is a drug which is both rewarding and reinforcing. ΔFosB, a gene transcription factor, is now known to be a critical component and common factor in the development of virtually all forms of behavioral and drug addictions, but not dependence.

Abdol Hamid Ghodse CBE was an academic in the field of substance abuse and addiction.

David F. Duncan is president of Duncan & Associates, a firm providing consultation on research design and data collection for behavioral and policy studies. He is also Clinical Associate Professor in the Department of Community Health at Brown University School of Medicine.

David C. Lewis was Professor Emeritus of Medicine and Community Health and the Donald G. Millar Distinguished Professor of Alcohol and Addiction Studies at Brown University.

Bertha Kalifon Madras is a professor of psychobiology in the Department of Psychiatry and the chair of the Division of Neurochemistry at Harvard Medical School, Harvard University. She served as associate director for public education in the division on Addictions at Harvard Medical School. Madras has published research in the areas of drug addiction, ADHD, and Parkinson's disease.

<span class="mw-page-title-main">Alan I. Leshner</span> American scientist & academic

Alan Leshner is an American psychologist who served as director of the National Institute on Drug Abuse, and the National Institute of Mental Health, has held senior positions at the National Science Foundation and the American Association for the Advancement of Science, and serves on the National Science Board.

Herbert David Kleber was an American psychiatrist and substance abuse researcher. His career, centered on the evidence-based treatment of addiction, focused on scientific approaches in place of punishment and moralisms. His career focused on pathology of addiction to help patients reduce the severe discomforts of withdrawal, avoid relapse and stay in recovery.

<span class="mw-page-title-main">Substance use disorder</span> Continual use of drugs (including alcohol) despite detrimental consequences

Substance use disorder (SUD) is the persistent use of drugs despite the substantial harm and adverse consequences to one's own self and others, as a result of their use. In perspective, the effects of the wrong use of substances that are capable of causing harm to the user or others, have been extensively described in different studies using a variety of terms such as substance use problems, problematic drugs or alcohol use, and substance use disorder.The National Institute of Mental Health (NIMH) states that "Substance use disorder (SUD) is a treatable mental disorder that affects a person's brain and behavior, leading to their inability to control their use of substances like legal or illegal drugs, alcohol, or medications. Symptoms can be moderate to severe, with addiction being the most severe form of SUD".Substance use disorders (SUD) are considered to be a serious mental illness that fluctuates with the age that symptoms first start appearing in an individual, the time during which it exists and the type of substance that is used. It is not uncommon for those who have SUD to also have other mental health disorders. Substance use disorders are characterized by an array of mental/emotional, physical, and behavioral problems such as chronic guilt; an inability to reduce or stop consuming the substance(s) despite repeated attempts; operating vehicles while intoxicated; and physiological withdrawal symptoms. Drug classes that are commonly involved in SUD include: alcohol (alcoholism); cannabis; opioids; stimulants such as nicotine (including tobacco), cocaine and amphetamines; benzodiazepines; barbiturates; and other substances.

<span class="mw-page-title-main">Mark S. Gold</span>

Mark S. Gold is an American physician, professor, author, and researcher on the effects of opioids, cocaine, tobacco, and other drugs as well as food on the brain and behavior. He is married to Janice Finn Gold.

<span class="mw-page-title-main">Michael Botticelli</span> American public health official

Michael P. Botticelli is an American public health official who served as the director of the White House Office of National Drug Control Policy (ONDCP) from March 2014 until the end of President Obama's term. He was named acting director after the resignation of Gil Kerlikowske, and received confirmation from the United States Senate in February 2015. Prior to joining ONDCP, he worked in the Massachusetts Department of Public Health. Following completion of his service as ONDCP Director, he became the executive director of the Grayken Center for Addiction Medicine at the Boston Medical Center.

About 1 in 7 Americans suffer from active addiction to a particular substance. Addiction can cause physical, psychological, and emotional harm to those who are affected by it. The American Society of Addiction Medicine defines addiction as "a treatable, chronic medical disease involving complex interactions among brain circuits, genetics, the environment, and an individual's life experiences. People with addiction use substances or engage in behaviors that become compulsive and often continue despite harmful consequences." In the world of psychology and medicine, there are two models that are commonly used in understanding the psychology behind addiction itself. One model is referred to as the disease model of addiction. The disease model suggests that addiction is a diagnosable disease similar to cancer or diabetes. This model attributes addiction to a chemical imbalance in an individual's brain that could be caused by genetics or environmental factors. The second model is the choice model of addiction, which holds that addiction is a result of voluntary actions rather than some dysfunction of the brain. Through this model, addiction is viewed as a choice and is studied through components of the brain such as reward, stress, and memory. Substance addictions relate to drugs, alcohol, and smoking. Process addictions relate to non-substance-related behaviors such as gambling, spending money, sexual activity, gaming, spending time on the internet, and eating.

<span class="mw-page-title-main">Charles P. O'Brien</span> American research scientist, medical educator (born 1939)

Charles P. O'Brien is a research scientist, medical educator and a leading expert in the science and treatment of addiction. He is board certified in neurology, psychiatry and addiction psychiatry. He is currently the Kenneth E. Appel Professor of Psychiatry, and vice chair of psychiatry, in the Perelman School of Medicine at the University of Pennsylvania.

Discrimination against drug addicts is a form of discrimination against people who suffer from a drug addiction.

Hendrée E. Jones is a researcher on women's substance abuse disorders and its impact on children. She is a professor in the Department of Obstetrics and Gynecology at the University of North Carolina School of Medicine, and adjunct professor in the University of North Carolina College of Arts & Sciences Department of Psychology and Neuroscience. Jones is the executive director of the UNC Horizons Program, which is a comprehensive drug treatment program for mothers and their drug-exposed children. She is a consultant for the Substance Abuse and Mental Health Services Administration, the United Nations, and the World Health Organization.

John F. Kelly is an American-based researcher and professor of addiction medicine at Harvard Medical School. He is the Founder and Director of the Massachusetts General Hospital Recovery Research Institute, Associate Director of the MGH Center for Addiction Medicine, and Program Director of the MGH Addiction Recovery Management Service.

<span class="mw-page-title-main">Addiction severity index</span> Clinical assessment tool

The Addiction Severity Index (ASI) is used to assess the severity of patient's addiction and analyse the need of treatment which has been in use for more than 2 decades since its publication in 1992. It is used in a variety of settings such as clinics, mental health services in the US, the Indian Health Service and several European countries. One of its major applications is as a clinical assessment tool for clinicians to determine the severity of the addictions and the necessity for treatment through probing the patients' conditions in both health and social issues. 7 aspects including medical health, employment/ support status, drug and alcohol use, illegal activity and legal status, family and social relationships and psychiatric health were inquired.

<span class="mw-page-title-main">Joseph R. Volpicelli</span> American psychiatrist

Joseph R. Volpicelli is an American psychiatrist, research scientist, medical academic, and expert in the treatment of addictive disorders. He is Professor Emeritus, Perelman School of Medicine at the University of Pennsylvania. He is board certified in neurology, psychiatry and addiction psychiatry. He currently is Medical Director at Volpicelli Center, an out-patient addiction treatment facility in Plymouth Meeting, Pennsylvania, as well as the Executive Director at Institute of Addiction Medicine, a non-profit research entity also in Plymouth Meeting, Pennsylvania.

References

  1. Archived April 13, 2009, at the Wayback Machine
  2. "Obama Administration Names A. Thomas McLellan Deputy ONDCP Director" (PDF) (Press release). 2010-04-10. Retrieved 2010-08-09.[ permanent dead link ]
  3. Imhof, John E.; Hirsch, Robert (2001). "Editorial: The Torch is Passed". Journal of Substance Abuse Treatment. 20 (1): 1–2. doi:10.1016/S0740-5472(00)00173-2.